FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310776688> ?p ?o ?g. }

• W4310776688 abstract "Abstract Background Immunotherapy with immune checkpoint inhibitors is associated with immune-related adverse events (irAEs). A positive correlation between treatment efficacy and irAEs has been reported. Clinical indicators are required for appropriate interventions, such as steroid administration, to prevent fatal outcomes. Nuclear receptor transcription factor 4a (Nr4a), which is involved in T-cell anergy, exhaustion, and regulatory T cells, were observed not only in thymocytes but in peripheral blood mononuclear cells. We describe a case of Stevens-Johnson syndrome (SJS) that was induced by a single dose of pembrolizumab and successfully treated with steroids, leading to complete remission of lung cancer during the monitoring of immune response indices, including Nr4a1 mRNA. Case presentation A 68-year-old male with squamous cell lung cancer (cT2aN3M0, stage IIIb) received a single dose of pembrolizumab (200 mg). On Day 21 of treatment, SJS appeared, and the patient was treated with prednisolone 60 mg/day, which was gradually tapered off. After the disappearance of the SJS symptoms, complete remission of cancer was achieved and was maintained for more than 1 year. Acute increases in the plasma IFN-γ and IL-17 concentrations and a decrease in IL-10 concentrations were observed at the onset of SJS. Simple regression analysis showed that these changes in IL-17, IFN-γ and IL-10 were significantly influenced by the decreased expression of Nr4a1 mRNA. The pembrolizumab levels and prednisolone doses significantly influenced the suppression of Nr4a1 mRNA levels. Although Nr4a1 mRNA levels in the current case fluctuated during the observation period, they were significantly lower than those in a nonresponding progressive-disease case, as well as a pembrolizumab-responding case with non-SJS but similar background. The suppression of Nr4a1 in current case, might result in upregulation of cytotoxic T cells and a reduction in functional regulatory T cells, promoting favorable antitumor immunity. Conclusion The immune responses involving Nr4a1 suppression might relate to complete remission of lung cancer in this case, despite causing SJS, which may be attributed to synergistic effects from pembrolizumab treatment and intervention with steroids. The current case indicates the preliminarily clinical benefit of evaluating Nr4a expression-related indices as the possible clinical covariates and may serve as a milestone for appropriate future chemotherapy interventions." @default.
• W4310776688 created "2022-12-17" @default.
• W4310776688 creator A5002458493 @default.
• W4310776688 creator A5003107419 @default.
• W4310776688 creator A5004272464 @default.
• W4310776688 creator A5039859624 @default.
• W4310776688 creator A5047594601 @default.
• W4310776688 creator A5051807148 @default.
• W4310776688 creator A5052575620 @default.
• W4310776688 creator A5056701685 @default.
• W4310776688 creator A5081662717 @default.
• W4310776688 date "2022-12-05" @default.
• W4310776688 modified "2023-10-14" @default.
• W4310776688 title "A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer" @default.
• W4310776688 cites W1513629354 @default.
• W4310776688 cites W1910012553 @default.
• W4310776688 cites W1973020652 @default.
• W4310776688 cites W1988200984 @default.
• W4310776688 cites W1989889553 @default.
• W4310776688 cites W2014750930 @default.
• W4310776688 cites W2056355344 @default.
• W4310776688 cites W2088749787 @default.
• W4310776688 cites W2095478283 @default.
• W4310776688 cites W2128229698 @default.
• W4310776688 cites W2773643507 @default.
• W4310776688 cites W2779503684 @default.
• W4310776688 cites W2893726457 @default.
• W4310776688 cites W2919428266 @default.
• W4310776688 cites W2921081828 @default.
• W4310776688 cites W2941271487 @default.
• W4310776688 cites W2977484833 @default.
• W4310776688 cites W2996617264 @default.
• W4310776688 cites W2997720498 @default.
• W4310776688 cites W3045946240 @default.
• W4310776688 cites W3127186093 @default.
• W4310776688 cites W3171467378 @default.
• W4310776688 cites W3202978616 @default.
• W4310776688 doi "https://doi.org/10.1186/s40780-022-00261-y" @default.
• W4310776688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36464708" @default.
• W4310776688 hasPublicationYear "2022" @default.
• W4310776688 type Work @default.
• W4310776688 citedByCount "1" @default.
• W4310776688 countsByYear W43107766882023 @default.
• W4310776688 crossrefType "journal-article" @default.
• W4310776688 hasAuthorship W4310776688A5002458493 @default.
• W4310776688 hasAuthorship W4310776688A5003107419 @default.
• W4310776688 hasAuthorship W4310776688A5004272464 @default.
• W4310776688 hasAuthorship W4310776688A5039859624 @default.
• W4310776688 hasAuthorship W4310776688A5047594601 @default.
• W4310776688 hasAuthorship W4310776688A5051807148 @default.
• W4310776688 hasAuthorship W4310776688A5052575620 @default.
• W4310776688 hasAuthorship W4310776688A5056701685 @default.
• W4310776688 hasAuthorship W4310776688A5081662717 @default.
• W4310776688 hasBestOaLocation W43107766881 @default.
• W4310776688 hasConcept C121608353 @default.
• W4310776688 hasConcept C126322002 @default.
• W4310776688 hasConcept C134018914 @default.
• W4310776688 hasConcept C197934379 @default.
• W4310776688 hasConcept C203014093 @default.
• W4310776688 hasConcept C2776256026 @default.
• W4310776688 hasConcept C2776715498 @default.
• W4310776688 hasConcept C2777701055 @default.
• W4310776688 hasConcept C2777761686 @default.
• W4310776688 hasConcept C2777990475 @default.
• W4310776688 hasConcept C2780057760 @default.
• W4310776688 hasConcept C71924100 @default.
• W4310776688 hasConcept C8891405 @default.
• W4310776688 hasConcept C90924648 @default.
• W4310776688 hasConceptScore W4310776688C121608353 @default.
• W4310776688 hasConceptScore W4310776688C126322002 @default.
• W4310776688 hasConceptScore W4310776688C134018914 @default.
• W4310776688 hasConceptScore W4310776688C197934379 @default.
• W4310776688 hasConceptScore W4310776688C203014093 @default.
• W4310776688 hasConceptScore W4310776688C2776256026 @default.
• W4310776688 hasConceptScore W4310776688C2776715498 @default.
• W4310776688 hasConceptScore W4310776688C2777701055 @default.
• W4310776688 hasConceptScore W4310776688C2777761686 @default.
• W4310776688 hasConceptScore W4310776688C2777990475 @default.
• W4310776688 hasConceptScore W4310776688C2780057760 @default.
• W4310776688 hasConceptScore W4310776688C71924100 @default.
• W4310776688 hasConceptScore W4310776688C8891405 @default.
• W4310776688 hasConceptScore W4310776688C90924648 @default.
• W4310776688 hasFunder F4320334764 @default.
• W4310776688 hasIssue "1" @default.
• W4310776688 hasLocation W43107766881 @default.
• W4310776688 hasLocation W43107766882 @default.
• W4310776688 hasLocation W43107766883 @default.
• W4310776688 hasLocation W43107766884 @default.
• W4310776688 hasOpenAccess W4310776688 @default.
• W4310776688 hasPrimaryLocation W43107766881 @default.
• W4310776688 hasRelatedWork W1591495472 @default.
• W4310776688 hasRelatedWork W1941578821 @default.
• W4310776688 hasRelatedWork W1996150995 @default.
• W4310776688 hasRelatedWork W2033320031 @default.
• W4310776688 hasRelatedWork W2134223583 @default.
• W4310776688 hasRelatedWork W3029766637 @default.
• W4310776688 hasRelatedWork W3041652591 @default.
• W4310776688 hasRelatedWork W3136661288 @default.
• W4310776688 hasRelatedWork W4225695268 @default.
• W4310776688 hasRelatedWork W4360983034 @default.

• next